| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
TNF-α
UTL-5g targets TNF-α, a pro-inflammatory cytokine that plays a central role in inflammation and immune regulation. By inhibiting TNF-α, UTL-5g reduces the inflammatory response and protects tissues from damage. It also reduces LPS-induced transcriptional activity mediated by a variety of immune-related transcription factors, including STAT1, STAT2, STAT3, and SMAD2-4. |
|---|---|
| ln Vitro |
RAW 264.7 macrophages are transfected with the appropriate reporter assay plasmids, pretreated with UTL-5g at 1, 10, or 50 µM for 60 min, and then challenged with 100 ng/ml LPS. Transcription factor activity is assessed after a 16-hour incubation. UTL-5g disrupts transcription factors when they exhibit a dose-dependent decline in activity in two experiments.
In vitro, UTL-5g is a TNF-α inhibitor. It reduces the production of TNF-α and other inflammatory cytokines. It has been shown to protect cells from cisplatin-induced toxicity. |
| ln Vivo |
UTL-5g (GBL-5g) reduces TGF-β and TNF-α levels that have been raised by lung irradiation[1].
UTL-5g (60 mg/kg; p.o.; daily for 4 days) exhibits beneficial effects in boosting survival rates and lengthening survival times[3]. In vivo, UTL-5g has been shown to reduce cisplatin-induced hepatotoxicity, nephrotoxicity, and bone marrow toxicity in animal models. It also has hepatoradioprotective effects. It is being studied as a potential chemoprotective agent to reduce the side effects of cancer chemotherapy. |
| Enzyme Assay |
In vitro enzyme/receptor binding assays for UTL-5g typically involve evaluating its inhibitory activity against TNF-α using ELISA or cell-based assays. The compound is incubated with TNF-α, and the inhibition of TNF-α binding to its receptor or the inhibition of TNF-α-induced signaling is measured.
|
| Cell Assay |
For in vitro cell-based assays, UTL-5g is dissolved in DMSO and applied to cultured cells such as macrophages or hepatocytes at concentrations ranging from 1-100 µM. The effects on TNF-α production, inflammatory cytokine expression, and cell viability are assessed after 1-24 hours of treatment.
|
| Animal Protocol |
In vivo animal studies for UTL-5g are typically conducted in rodent models of cisplatin-induced toxicity. UTL-5g is administered orally or intraperitoneally at doses ranging from 1-50 mg/kg. Efficacy is evaluated by measuring markers of hepatotoxicity (e.g., ALT, AST), nephrotoxicity (e.g., BUN, creatinine), and bone marrow toxicity (e.g., blood cell counts).
|
| ADME/Pharmacokinetics |
UTL-5g has a molecular formula of C₁₁H₈Cl₂N₂O₂ and a molecular weight of 271.1 g/mol. It is soluble in DMSO (54 mg/mL). It is typically stored as a powder at -20°C.
|
| Toxicity/Toxicokinetics |
UTL-5g is considered to have a manageable toxicity profile. As a research chemical, it is not intended for human therapeutic use. Appropriate safety precautions, including the use of personal protective equipment, should be followed when handling the compound.
|
| References | |
| Additional Infomation |
UTL-5g is a novel small-molecule TNF-α inhibitor with chemoprotective and hepatoradioprotective effects. It is also known as GBL-5g. UTL-5g is not approved for clinical use and is intended for research purposes only. It is supplied by various research chemical suppliers for non-human use.
|
| Molecular Formula |
C11H8CL2N2O2
|
|---|---|
| Molecular Weight |
271.09
|
| Exact Mass |
269.996
|
| Elemental Analysis |
C, 48.74; H, 2.97; Cl, 26.15; N, 10.33; O, 11.80
|
| CAS # |
646530-37-2
|
| Related CAS # |
646530-37-2
|
| PubChem CID |
17173847
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.615
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
291
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC(=NO1)C(=O)NC2=C(C=C(C=C2)Cl)Cl
|
| InChi Key |
ULPKSWAQDCJLMN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H8Cl2N2O2/c1-6-4-10(15-17-6)11(16)14-9-3-2-7(12)5-8(9)13/h2-5H,1H3,(H,14,16)
|
| Chemical Name |
N-(2,4-dichlorophenyl)-5-methyl-1,2-oxazole-3-carboxamide
|
| Synonyms |
UTL5g; UTL 5g; UTL-5g
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 54~100 mg/mL(199.2~368.9 mM)
Ethanol~ ~4 mg/mL(14.8 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6888 mL | 18.4441 mL | 36.8881 mL | |
| 5 mM | 0.7378 mL | 3.6888 mL | 7.3776 mL | |
| 10 mM | 0.3689 mL | 1.8444 mL | 3.6888 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
